News

Can-Fite's Namodenoson Shows Promising Results in Cirrhosis Treatment

Can-Fite's Namodenoson Shows Promising Results in Cirrhosis Treatment

Significant Clinical Findings with Namodenoson Treatment

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) has shared groundbreaking news regarding its compassionate use program for patients with decompensated liver cirrhosis. A patient treated with Namodenoson showed a remarkable improvement: a complete resolution of esophageal varices, confirmed through thorough endoscopic examination. This milestone marks an important case in the clinical landscape of treating advanced liver cirrhosis.

The Challenge of Esophageal Varices

Esophageal varices often arise as a critical complication in patients with advanced liver disease, posing significant risks including life-threatening gastrointestinal bleeding. The complete disappearance of varices in a patient with decompensated cirrhosis is an exceptional outcome, suggesting that Namodenoson may possess a disease-modifying capability that merits further investigation.

Expert Insights

Prof. Ohad Etzion, Chief of Gastroenterology and Liver Diseases at Soroka Medical Center, commented on these findings, highlighting Namodenoson’s potential to alleviate significant risks associated with advanced liver diseases. Such insights offer hope and direction for future clinical developments of the drug.

Ongoing Clinical Trials of Namodenoson

Currently, Namodenoson is the focus of a Phase III clinical trial aimed at treating hepatocellular carcinoma (HCC) in patients with advanced liver disease classified as Child-Pugh B. Data from compassionate use cases like this one will contribute valuable insights into the broader potential of Namodenoson in clinical settings.

Global Context of Liver Disease

With estimates of over 10.6 million individuals affected by decompensated cirrhosis globally, the need for new and effective treatment strategies is urgent. The American Liver Foundation brings to light a stark reality: the number of patients requiring liver transplants far exceeds the available donor organs. This situation highlights a critical demand for innovative therapies, with the U.S. liver cirrhosis treatment market expected to soar to around $15 billion by the end of the decade.

Understanding Namodenoson

Namodenoson operates as a small, orally bioavailable drug that selectively binds to the A3 adenosine receptor (A3AR). This preferential binding to diseased cells while sparing healthy ones is crucial to its safety profile. Currently, Namodenoson is also in pivotal trials for other conditions, including a Phase IIb trial focusing on Metabolic Dysfunction-associated Steatohepatitis (MASH) and a Phase IIa trial for pancreatic cancer.

Can-Fite BioPharma’s Commitment

Can-Fite BioPharma, with its innovative approach, is dedicated to addressing multi-billion-dollar markets, including those related to liver, cancer, and inflammatory diseases. Their pipeline holds promise, particularly with drugs like Piclidenoson, which has already reported positive topline results for psoriasis treatments. Furthermore, Namodenoson has been awarded Orphan Drug Designation in both the U.S. and Europe, as well as Fast Track status for treating HCC.

Conclusion: Toward a Brighter Future

The results from the compassionate use of Namodenoson convey a message of optimism for patients battling advanced liver diseases. As clinical research progresses, the hope is that many more lives can be positively impacted. Efficacy and safety remain at the forefront of Can-Fite's mission as they strive to develop innovative therapies for those in need.

Frequently Asked Questions

What is Namodenoson used for?

Namodenoson is being evaluated for the treatment of hepatocellular carcinoma and other liver-related conditions.

What were the results of the compassionate use study?

A patient with decompensated cirrhosis showed a complete resolution of esophageal varices after treatment with Namodenoson.

Why is the resolution of esophageal varices important?

Esophageal varices pose a high risk of serious bleeding, making their resolution a significant clinical achievement in treating advanced liver disease.

What is the market outlook for liver cirrhosis treatments?

The market for liver cirrhosis treatments is projected to grow to approximately $15 billion by 2030, reflecting a strong demand for effective therapies.

How is Can-Fite BioPharma advancing its research?

Can-Fite is committed to developing therapies with a focus on both safety and efficacy, with multiple clinical trials ongoing to explore the full potential of their drug candidates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 253

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 112

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
UN Integrity Accelerator Targets Corporate Corruption

Updated Category News Views 10

Corruption rarely arrives wearing a villain costume; it shows up as a rushed payment, a friendly intermediary, or a contract nobody wants examined too closely. That is why the United Nations Global Compact's new Business Integrity Accelerator deserves a sober look. Launched November 18, 2026, the programme is not a magic shield, and nobody should sell it as one. But it...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 138

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 71

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 81

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 103

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming $100 into a Remarkable Asset with ISRG

Updated Category News Views 310

Investing in Intuitive Surgical: A Decade of Growth Investing in stocks can often lead to impressive returns, and when it comes to Intuitive Surgical (NASDAQ: ISRG), this statement holds particularly true over the past decade. With a remarkable annualized return of 24.63%, Intuitive Surgical has substantially outperformed the market, making it an attractive consideration...

Continue Reading
Giftify, Inc. Empowers Consumers Amid Increasing Food Costs

Updated Category News Views 181

How Giftify, Inc. is Supporting Consumers with Savings In a time where food prices are skyrocketing, especially in the grocery sector, Giftify, Inc. (NASDAQ: GIFT), the company behind the CardCash.com platform, is stepping up to support consumers. With rising egg prices and the increasing impact of inflation, Giftify is providing a practical solution for everyday...

Continue Reading
HCA Healthcare Posts Strong Results, Showcases Growth Potential

Updated Category News Views 315

HCA Healthcare Inc. Surpasses Expectations with Q3 Results HCA Healthcare Inc. (NYSE: HCA), recognized as one of the largest hospital operators in the country, recently shared its financial results for the third quarter of 2025. The company reported a notable increase in its financial metrics, showcasing resilience and growth amidst the evolving healthcare landscape....

Continue Reading
MedEx Ambulance Addresses Security Incident Resolution Steps

Updated Category News Views 379

Understanding the Recent Data Security Incident MedEx Ambulance, known for its dedication to emergency services, has recently faced a troubling data security incident. This incident has raised concerns about unauthorized access to both patient health records and employee personal details. Although operations have continued without disruption, MedEx feels it's crucial to...

Continue Reading
Blue Apron Tops Rankings for Home Meal Delivery Services

Updated Category News Views 139

Blue Apron Achieves Top Rank for Home Meal Delivery Blue Apron has risen to the highest rank for home-cooked meals through an extensive evaluation by Expert Consumers. This independent assessment focused on various meal delivery services, gauging them based on ingredient quality, recipe clarity, sourcing transparency, ease of use, and overall support for home cooking. Why...

Continue Reading